

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

THE CLINICAL TRIAL APPROVAL FOR SIM0689 (PD-1/VEGF BISPECIFIC ANTIBODY) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that SIM0689, a bispecific antibody targeting PD-1/VEGF and self-developed by the Group, has received the Clinical Trial Approval issued by the National Medical Products Administration (國家藥品監督管理局) of China, and is intended for commencing the clinical trial for advanced solid tumors.

ABOUT SIM0689

SIM0689 is a bispecific antibody simultaneously targeting programmed cell death protein 1 (PD-1) and specific epitope of vascular endothelial growth factor (VEGF). By relieving tumor cell immunosuppression and anti-angiogenesis, SIM0689 exerts potent anti-tumor activity. In multiple humanized mouse efficacy models, SIM0689 demonstrated excellent anti-tumor efficacy even at low doses, with its overall efficacy significantly superior to that of the same type of molecules, indicating its broad application prospects in multiple solid tumors.

ABOUT THE GROUP

The Company is an innovation and R&D-driven pharmaceutical company and the Group has established a “State Key Laboratory of Neurology and Oncology Drug Development”. The Group focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “for patients, for life”. Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Executive Director

Hong Kong, June 12, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.